Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 4, 2010, Pages 408-416

  Yarbrough, William M ^a,b   Mukherjee, Rupak ^a   Stroud, Robert E ^a   Meyer, Evan C ^a   Escobar, G Patricia ^a   Sample, Jeffrey A ^a   Hendrick, Jennifer W ^a   Mingoia, Joseph T ^a   Spinale, Francis G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Caspase inhibition; Left ventricular; Myocardial infarction; Remodeling

Indexed keywords

ACTIN; CASPASE; CASPASE 3; CASPASE INHIBITOR; GELATINASE A; IDN 6734; MYOSIN; SODIUM CHLORIDE; TROPONIN C; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG; BENZYLOXYCARBONYL-VALYL-ALANYL-ASPARTIC ACID; COLLAGEN; CYSTEINE PROTEINASE INHIBITOR; ENZYME PRECURSOR; GELATINASE; MATRIX METALLOPROTEINASE; OLIGOPEPTIDE; PROGELATINASE; RECOMBINANT PROTEIN; TROPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HEMODYNAMICS; MORPHOMETRICS; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; STEADY STATE; SWINE; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTINS; ANIMALS; BLOOD PRESSURE; CASPASE 3; CASPASE INHIBITORS; CASPASES; COLLAGEN; CYSTEINE PROTEINASE INHIBITORS; ENZYME PRECURSORS; GELATINASES; HEART; HEART VENTRICLES; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; MYOSINS; OLIGOPEPTIDES; RECOMBINANT PROTEINS; SUS SCROFA; TROPONIN; TROPONIN I; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 77951732292     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d4ca66     Document Type: Article

References (30)

1. Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-210.
2. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest. 1979;40:633-644.
3. Gill C, Mestril R, Samali A. Losing heart: the role of apoptosis in heart disease-a novel therapeutic target? FASEB J. 2002;16:135-146.
4. Mani K, Kitsis RN. Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol. 2003;41:761-764.
5. Abbate A, Biondi-Zoccai GG, Bussani R, et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol. 2003; 41:753-760.
6. Huang JQ, Radinovic S, Rezaiefar P, et al. In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia. Eur J Pharmacol. 2000;402:139-142.
7. Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol. 1999;31:1709-1715.
8. Yaoita H, Ogawa K, Maehara K, et al. Attenuation of ischemia/ reperfusion injury in rats by a caspase inhibitor. Circulation. 1998;97: 276-281.
9. Kovacs P, Bak I, Szendrei L, et al. Non-specific caspase inhibition reduces infarct size and improves post-ischaemic recovery in isolated ischaemic/ reperfused rat hearts. Naunyn Schmiedebergs Arch Pharmacol. 2001;364: 501-507.
10. Okamura T, Miura T, Takemura G, et al. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischemiareperfused rat heart. Cardiovasc Res. 2000;45:642-650.
11. Communal C, Sumandea M, de Tombe P, et al. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA. 2002; 99:6252-6256.
12. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107:618-625.
13. Yarbrough WM, Mukherjee R, Brinsa TA, et al. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003;125:602-610.
14. Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003;108:1753-1759. (Pubitemid 37243666)
15. McElmurray JH, Mukherjee R, New RB, et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther. 1999;291:799-811. (Pubitemid 29503556)
16. Ytrehus K, Liu Y, Tsuchida A, et al. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol. 1994;267:H2383-H2390.
17. Coker ML, Thomas CV, Clair MJ, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 1998;274:H1516-H1523.
18. Eble DM,Walker JD, Mukherjee R, et al. Myosin heavy chain synthesis is increased in a rabbit model of heart failure. Am J Physiol. 1997;272: H969-H978.
19. Spinale FG, Zellner JL, Johnson WS, et al. Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol. 1996;28:1591-1608.
20. Gerdes AM, Onodera T, Tamura T, et al. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998;4:343-348.
21. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
22. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinases-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
23. Rohde L, Ducharme A, Arroyo L, et al. Matrix metalloproteinases inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063-3070.
24. Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247-2259.
25. Cheng W, Kajstura J, Nitahara JA, et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res. 1996; 226:316-327.
26. Joffs C, Gunasinghe H, Multani MM, et al. Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases. Ann Thorac Surg. 2001;71:1518-1523.
27. Etoh T, Joffs C, Deschamps A, et al. Myocardial and interstitial matrix metalloproteinases activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol. 2001;281:H987-H994.
28. Minatoguchi S, Kariya T, Uno Y, et al. Caspase-dependent and serine protease-dependent DNA fragmentation of myocytes in the ischemiareperfused rabbit heart: these inhibitors do not reduce infarct size. Jpn Circ J. 2001;65:907-911.
29. Park M, Shen Y-T, Gaussin V, et al. Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol. 2009; 297:H785-H789.
30. Laplante P, Sirois I, Raymond MA, et al. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ. 2010;17:2941-3303